Data from FDA’s Mini Sentinel program was among the key data used in the agency’s decision not to change its recommendations for use of Pradaxa (dabigatran) following reports of severe bleeding events.
The agency said in a Nov. 2 drug safety communication that results from a Mini Sentinel assessment indicated bleeding rates associated with new users of Boehringer Ingelheim GMBH’s Pradaxa...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?